CLRB — Cellectar Biosciences, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1279704 ·
Last close
$0.92
Market Cap
$9.24M
52W High
$4.70
52W Low
$0.90
ADV30
142,323
Next earnings
—
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -8,104,015 -7,974,743 29,743,263 24,582,115 7,327,897
Jun 2026 0 — -7,196,012 -6,930,653 36,639,086 33,993,982 6,767,253
Mar 2026 0 — -5,793,942 -5,653,946 11,119,761 8,347,090 7,784,674
Dec 2025 0 — -5,690,629 -5,295,221 14,978,321 13,196,033 6,441,157

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-24,611,750
Investing CF
$-9,258
Financing CF
$13,031,528
CapEx
$-3,378
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.77
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-289,692,843
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-26,784,598
Pretax Income TTM
$-25,854,563
Interest Exp TTM
—
Analysts
4

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -22,979,844 -21,791,037 14,978,321 6,441,157 8,537,164 -23,118,217
Dec 2024 0 -51,777,698 -44,581,446 25,474,047 11,179,366 14,294,681 -47,583,001
Dec 2023 0 -38,960,643 -42,770,610 12,075,580 27,234,548 -15,158,968 -32,376,974
Dec 2022 0 -28,813,773 -31,792,618 21,589,790 13,436,546 8,153,244 -25,222,301

TTM Snapshot

Revenues TTM
$25,841,416
NetIncome TTM
$-22,323,696
OpCashFlow TTM
—
Assets (Latest)
$36,639,086
Forward EPS
$-2.03

Peers — same industry

TickerNameMarket CapLastDaily %
GDTC CytoMed Therapeutics Ltd $9.27M $0.78 —
PTN PALATIN TECHNOLOGIES INC $9.55M $5.36 —
PBM PSYENCE BIOMEDICAL LTD. $9.57M $2.51 —
BIVI BIOVIE INC. $9.61M $1.00 —
BFRI Biofrontera Inc. $8.81M $0.59 —

News headlines (Yahoo Finance, 1h cache)

Cellectar Biosciences, Inc. Q3 2026 Earnings Call Summary
2026-11-11 13:30 · Yahoo
Cellectar (CLRB) Q3 2026 Earnings Call Transcript
2026-11-11 03:58 · Yahoo
Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
2026-11-10 12:15 · Yahoo
Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Expo
2026-11-04 14:00 · Yahoo
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
2026-11-02 13:00 · Yahoo
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
2026-10-27 11:15 · Yahoo
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Works
2026-10-15 11:00 · Yahoo
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Worksho
2026-09-29 11:30 · Yahoo
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript
2026-08-20 14:13 · Yahoo
Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ...
2026-08-17 21:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.